PolarityTE, Inc. — Cyborg Score 6/10

Solid
Regenerative tissue engineering and wound healing

Strategic Profile

The flagship product, SkinTE, is used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. SkinTE has received Breakthrough Therapy Designation (BTD) from the FDA for the treatment of Wagner Grade 1 Diabetic Foot Ulcers (DFU), positioning the company for accelerated regulatory pathways. Final completion and last patient visit are expected by November 2025, with top-line results anticipated in the first quarter of 2026.

Cyborg Score Rationale

PolarityTE demonstrates meaningful clinical progress with FDA Breakthrough Designation and ongoing Phase 3 studies, but faces typical clinical-stage biotech risks. The company operates at limited scale with approximately 22 employees and relies on a single product candidate in active development.

Top Insights

  • SkinTE received FDA Breakthrough Therapy Designation for diabetic foot ulcers, enabling expedited development pathways and enhanced FDA engagement
  • Phase 3 pivotal study for chronic cutaneous ulcer indication expected to deliver top-line results in Q1 2026, a critical near-term catalyst
  • New AMA CPT codes (effective July 2026) provide reimbursement framework for SkinTE procedures, reducing post-approval commercialization barriers
  • Asset acquisition by Grander Acquisition LLC (August 2023) provided capital stabilization and clear pathway to BLA submission for two pivotal studies

Named Competitors

  • Apligraf — Bioengineered skin substitute for wounds and ulcers
  • EpiFix — Placental membrane allograft for wound healing
  • GraftJacket — Regenerative tissue matrix scaffold

Recent Developments

  • (August 2023) Grander Acquisition LLC completed acquisition of substantially all PolarityTE assets including SkinTE and open IND
  • (2025) AMA published new Category III CPT codes for SkinTE products, effective July 2026
  • (Expected Q1 2026) Top-line results anticipated from Phase 3 diabetic foot ulcer study

Open the full interactive PolarityTE, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →